| |
Pooled data
|
Etanercept
|
Adalimumab
|
|---|
| |
Adjusted mean changes (95% CI)
|
P-value
|
Adjusted mean changes (95% CI)
|
P-value
|
Adjusted mean changes (95% CI)
|
P-value
|
|---|
| |
<4 years
|
≥4 years
| |
<4 years
|
≥4 years
| |
<4 years
|
≥4 years
| |
|---|
|
BASDAI
|
3.2 (2.7, 3.7)
|
1.7 (1.1, 2.2)
|
0.001
|
3.1 (2.6, 3.6)
|
1.8 (1.1, 2.6)
|
0.008
|
3.2 (2.2, 4.3)
|
1.6 (0.9, 2.3)
|
0.02
|
|
BASFI
|
2.4 (2, 2.9)
|
1.2 (0.7, 1.6)
|
0.001
|
2.4 (1.9, 2.8)
|
1.2 (0.5, 1.8)
|
0.006
|
2.5 (1.5, 3.5)
|
1.3 (0.5, 2)
|
0.06
|
|
BASMI
|
0.3 (0, 0.6)
|
−0.1 (−0.4, 0.2)
|
0.09
|
0.4 (0.1, 0.7)
|
−0.02 (−0.5, 0.4)
|
0.16
|
0.02 (−0.6, 0.6)
|
−0.1 (−0.5, 0.3)
|
0.74
|
|
ASDAS
|
1.6 (1.4, 1.8)
|
0.9 (0.7, 1.1)
|
0.001
|
1.5 (1.3, 1.8)
|
1.1 (0.8, 1.4)
|
0.04
|
1.7 (1.2, 2.1)
|
0.8 (0.5, 1.1)
|
0.003
|
|
CRP*
|
1.6 (1.5, 2)
|
1.6 (1.4, 1.8)
|
0.72
|
1.5 (1.4, 1.8)
|
1.6 (1.4, 2.0)
|
0.60
|
2.2 (1.6, 3.0)
|
1.5 (1.2, 1.8)
|
0.06
|
|
MRI SIJ
|
3.5 (2.9, 4.1)
|
3 (2.3, 3.6)
|
0.28
|
3.9 (3.3, 4.6)
|
3.7 (2.8, 4.6)
|
0.71
|
7.0 (3.8, 10.1)
|
2.7 (0.7, 4.7)
|
0.04
|
- *Log-transformed CRP results were back transformed; p-value <0.05 was taken to indicate statistically significant differences between two groups; adjusted mean changes from baseline under treatment with etanercept or adalimumab (95% CI). Outcome differences were adjusted for baseline status (see Methods). BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; BASMI, Bath ankylosing spondylitis metrology index; ASDAS, ankylosing spondylitis disease activity score; CRP, C-reactive protein in mg/l; MRI, magnetic resonance imaging; SIJ sacroiliac joint.
